Dataset Information

Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

ABSTRACT: BACKGROUND:Although both men and women use e-cigarettes, most preclinical nicotine research has focused on its effects in male rodents following injection. The goals of the present study were to develop an effective e-cigarette nicotine delivery system, to compare results to those obtained after subcutaneous (s.c.) injection, and to examine sex differences in the model. METHODS:Hypothermia and locomotor suppression were assessed following aerosol exposure or s.c. injection with nicotine in female and male mice. Subsequently, plasma and brain concentrations of nicotine and cotinine were measured. RESULTS:Passive exposure to nicotine aerosol produced concentration-dependent and mecamylamine reversible hypothermic and locomotor suppressant effects in female and male mice, as did s.c. nicotine injection. In plasma and brain, nicotine and cotinine concentrations showed dose/concentration-dependent increases in both sexes following each route of administration. Sex differences in nicotine-induced hypothermia were dependent upon route of administration, with females showing greater hypothermia following aerosol exposure and males showing greater hypothermia following injection. In contrast, when they occurred, sex differences in nicotine and cotinine levels in brain and plasma consistently showed greater concentrations in females than males, regardless of route of administration. DISCUSSION:In summary, the e-cigarette exposure device described herein was used successfully to deliver pharmacologically active doses of nicotine to female and male mice. Further, plasma nicotine concentrations following exposure were similar to those after s.c. injection with nicotine and within the range observed in human smokers. Future research on vaped products can be strengthened by inclusion of translationally relevant routes of administration.

SUBMITTER: Lefever TW

PROVIDER: S-EPMC5327853 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Lefever Timothy W TW Lee Youn O K YO Kovach Alexander L AL Silinski Melanie A R MA Marusich Julie A JA Thomas Brian F BF Wiley Jenny L JL

Drug and alcohol dependence 20170118

<h4>Background</h4>Although both men and women use e-cigarettes, most preclinical nicotine research has focused on its effects in male rodents following injection. The goals of the present study were to develop an effective e-cigarette nicotine delivery system, to compare results to those obtained after subcutaneous (s.c.) injection, and to examine sex differences in the model.<h4>Methods</h4>Hypothermia and locomotor suppression were assessed following aerosol exposure or s.c. injection with ni ...[more]

PMID: 28157590

Similar Datasets

Project description:Cigarette smoking is a tough addiction to break. Therefore, improved approaches to smoking cessation are necessary. The electronic-cigarette (e-Cigarette), a battery-powered electronic nicotine delivery device (ENDD) resembling a cigarette, may help smokers to remain abstinent during their quit attempt or to reduce cigarette consumption. Efficacy and safety of these devices in long-term smoking cessation and/or smoking reduction studies have never been investigated.In this prospective proof-of-concept study we monitored possible modifications in smoking habits of 40 regular smokers (unwilling to quit) experimenting the 'Categoria' e-Cigarette with a focus on smoking reduction and smoking abstinence. Study participants were invited to attend a total of five study visits: at baseline, week-4, week-8, week-12 and week-24. Product use, number of cigarettes smoked, and exhaled carbon monoxide (eCO) levels were measured at each visit. Smoking reduction and abstinence rates were calculated. Adverse events and product preferences were also reviewed.Sustained 50% reduction in the number of cig/day at week-24 was shown in 13/40(32.5%) participants; their median of 25 cigs/day decreasing to 6 cigs/day (p < 0.001). Sustained 80% reduction was shown in 5/40(12.5%) participants; their median of 30 cigs/day decreasing to 3 cigs/day (p = 0.043). Sustained smoking abstinence at week-24 was observed in 9/40(22.5%) participants, with 6/9 still using the e-Cigarette by the end of the study. Combined sustained 50% reduction and smoking abstinence was shown in 22/40 (55%) participants, with an overall 88% fall in cigs/day. Mouth (20.6%) and throat (32.4%) irritation, and dry cough (32.4%) were common, but diminished substantially by week-24. Overall, 2 to 3 cartridges/day were used throughout the study. Participants' perception and acceptance of the product was good.The use of e-Cigarette substantially decreased cigarette consumption without causing significant side effects in smokers not intending to quit (http://ClinicalTrials.gov number NCT01195597).

Project description:IntroductionThe subjective experience of positive and negative effects likely contributes to e-cigarette use, and the Modified Cigarette Evaluation Questionnaire (MCEQ) previously has been adapted to assess the reinforcing and aversive effects of vaping. However, the psychometric properties of the MCEQ for use with e-cigarettes have not been established.Aims and methodsWe examined the psychometric properties of the Modified E-cigarette Evaluation Questionnaire (MECEQ) within a sample of 857 adults who recently used e-cigarettes in a smoking cessation attempt (52.4% male; 40.84 [12.25] years old; 62.8% non-Hispanic white; 22.4% daily e-cigarette users). Analyses included confirmatory factor analysis of the original structure, exploratory/confirmatory factor analyses to identify the alternate latent structure(s), internal consistency, measurement invariance, between-group differences, and test-criterion relationships with vaping-related outcomes.ResultsThe original five-factor structure and a novel four-factor structure were supported. Each was scalar invariant across several participant subgroups (eg, current smoking status, daily vaping status). All multi-item subscales were internally consistent. Both versions detected several between-group differences. For example, current smokers reported stronger aversive effects than did exclusive e-cigarette users. Finally, adjusted relationships between both MECEQ versions and vaping-related outcomes provided evidence for concurrent validity.ConclusionsThe five-factor and four-factor versions of the MECEQ evidenced good-to-excellent internal consistency, scalar measurement invariance, and concurrent relationships with vaping-related outcomes. While both versions could be used to assess subjective vaping effects in adults with histories of cigarette smoking and vaping, additional research is needed to evaluate the applicability of these factor structures to other samples (eg, e-cigarette users with no smoking history, youth).ImplicationsAlthough the MCEQ has been adapted in previously published studies to assess the subjective reinforcing and aversive effects of vaping, the psychometric foundation necessary for doing so had not been established. We showed that the MECEQ can be scored using the original five-factor MCEQ format or using a newly identified four-factor structure. Both versions evidenced construct validity, internal consistency, measurement invariance (permitting between-group comparisons), and concurrent validity with vaping-related outcomes. Results strengthen the interpretability of previously published work using the five-factor MCEQ structure and provide an alternative scoring approach for vaping-specific subjective effects.

Project description:IntroductionCharacterization of aerosols generated by electronic cigarettes (e-cigarettes) is one method used to evaluate the safety of e-cigarettes. While some researchers have modified smoking machines for e-cigarette aerosol generation, these machines are either not readily available, not automated for e-cigarette testing or have not been adequately described. The objective of this study was to build an e-cigarette vaping machine that can be used to test, under standard conditions, e-liquid aerosolization and nicotine and toxicant delivery.MethodsThe vaping machine was assembled from commercially available parts, including a puff controller, vacuum pump, power supply, switch to control current flow to the atomizer, three-way value to direct air flow to the atomizer, and three gas dispersion tubes for aerosol trapping. To validate and illustrate its use, the variation in aerosol generation was assessed within and between KangerTech Mini ProTank 3 clearomizers, and the effect of voltage on aerosolization and toxic aldehyde generation were assessed.ResultsWhen using one ProTank 3 clearomizer and different e-liquid flavors, the coefficient of variation (CV) of aerosol generated ranged between 11.5% and 19.3%. The variation in aerosol generated between ProTank 3 clearomizers with different e-liquid flavors and voltage settings ranged between 8.3% and 16.3% CV. Aerosol generation increased linearly at 3-6V across e-liquids and clearomizer brands. Acetaldehyde, acrolein, and formaldehyde generation increased markedly at voltages at or above 5V.ConclusionThe vaping machine that we describe reproducibly aerosolizes e-liquids from e-cigarette atomizers under controlled conditions and is useful for testing of nicotine and toxicant delivery.ImplicationsThis study describes an electronic cigarette vaping machine that was assembled from commercially available parts. The vaping machine can be replicated by researchers and used under standard conditions to generate e-cigarette aerosols and characterize nicotine and toxicant delivery.

Dataset Information

Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Publications

Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets